A prospective study to assess the clinical utility of serum HER2 extracellular domain in breast cancer with HER2 overexpression

[1] Wolff AC(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-4013

[2] Hammond ME(2011)The human epidermal growth factor receptor 2 (HER2) Clin Chem Lab Med 50 23-30

[3] Hicks DG(1984)The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 312 513-516

[4] Tafe LJ(2012)Challenges in the clinical utility of the serum test for HER2 ECD Biochim Biophys Acta 1826 199-208

[5] Tsongalis GJ(2012)HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer Cancer Treat Rev 38 133-142

[6] Schechter AL(2002)The HER2 extracellular domain as a prognostic and predictive factor in breast cancer Clin Breast Cancer 3 125-135

[7] Stern DF(1998)Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy J Clin Oncol 16 2409-2416

[8] Vaidyanathan L(2012)Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration PLoS Med 9 e1001216-1693

[9] Lam L(2009)Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer J Clin Oncol 27 1685-1705

[10] McAndrew N(2009)Value and limitations of measuring HER2 extracellular domain in the serum of breast cancer patients J Clin Oncol 27 1694-196

[1] Wolff AC(2013)Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 31 3997-4013

[2] Hammond ME(2011)The human epidermal growth factor receptor 2 (HER2) Clin Chem Lab Med 50 23-30

[3] Hicks DG(1984)The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 312 513-516

[4] Tafe LJ(2012)Challenges in the clinical utility of the serum test for HER2 ECD Biochim Biophys Acta 1826 199-208

[5] Tsongalis GJ(2012)HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer Cancer Treat Rev 38 133-142

[6] Schechter AL(2002)The HER2 extracellular domain as a prognostic and predictive factor in breast cancer Clin Breast Cancer 3 125-135

[7] Stern DF(1998)Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy J Clin Oncol 16 2409-2416

[8] Vaidyanathan L(2012)Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration PLoS Med 9 e1001216-1693

[9] Lam L(2009)Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer J Clin Oncol 27 1685-1705

[10] McAndrew N(2009)Value and limitations of measuring HER2 extracellular domain in the serum of breast cancer patients J Clin Oncol 27 1694-196